

Avapritinib (AYVAKIT) in Advanced Systemic Mastocytosis

Criteria for Use

November 2023

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Exclusion Criteria

If ANY of the following are selected, the patient will NOT meet criteria for avapritinib.

- Platelet count $< 50 \times 10^9/L$
- Unmanageable drug-drug interaction
- Pregnancy
- Lactating

Inclusion Criteria

ALL of the following must be selected in order to meet criteria:

- Documented diagnosis of one of the following subtypes of advanced systemic mastocytosis: aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast cell leukemia.
- Prescribed and monitored by a VA / VA Community Care hematologist / oncologist
- Goals of care and role of Palliative Care consult have been discussed and documented.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3

Additional Inclusion Criteria

Select if appropriate.

- For patients who can become pregnant and patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception.
- For patients who are breastfeeding/lactating: Advised to avoid providing breastmilk during therapy and for 2 weeks after the final dose

Other Justification

Prepared: November 2023 by Francine Goodman, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM).

Contact: Bernadette Heron, PharmD, BCOP, National PBM Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)
